GO:0019901 protein kinase binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019901 (protein kinase binding) is a molecular function describing the selective, non-covalent binding of a protein to a protein kinase enzyme.
• Protein kinase binding is the molecular basis of substrate recognition, scaffold assembly, and inhibitor action, and it can occur at sites distinct from the ATP pocket.
• Binding proteins can act as inhibitors, anchors, or scaffolds, as shown for FAM53C, which binds and cytosolic-anchors DYRK1A.
• The druggability of kinase binding interfaces is well established, with trametinib binding KSR-bound MEK illustrating allosteric and complex-directed recognition.
• Binding-site classification and molecular modeling are established methods for predicting and rationalizing protein kinase binding.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential for testing the causal role of protein kinase binding interactions in cells.
Description
GO:0019901, protein kinase binding, is a molecular function defined as binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. In practical terms, it describes the physical association between a protein and a kinase enzyme, an interaction that underlies substrate recruitment, scaffold assembly, and the action of many kinase inhibitors. Because protein kinases are central regulators of signaling, cell cycle, and metabolism, the proteins that bind them are equally important for understanding how phosphorylation is targeted and controlled.
protein kinase binding At A Glance
| GO ID | GO:0019901 |
|---|---|
| GO term | protein kinase binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to a protein kinase enzyme, thereby mediating substrate recognition, inhibition, anchoring, or scaffold assembly |
| Definition source | QuickGO definition: Binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate |
| Related activity | Protein kinase inhibitor activity, kinase substrate recognition, and allosteric regulation |
| Experimental readouts | Binding assays, kinase activity assays, structural biology, and cellular phosphorylation profiling |
What Is GO:0019901?
Protein kinase binding (GO:0019901) is the molecular function of selectively and non-covalently interacting with a protein kinase enzyme. The QuickGO definition specifies binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate. This function does not require that the binding protein be a substrate; it may be an inhibitor, an anchoring protein, a scaffold, or a regulatory subunit. Binding can occur at the ATP pocket, at allosteric sites, or at protein-protein interfaces, and it is often the first step in kinase regulation or inhibition.
Why Is protein kinase binding Important in Cell Biology?
Protein kinase binding is important because it determines which kinases are active, where they localize, and which substrates they phosphorylate. Many human diseases, including cancers and neurological disorders, involve dysregulated kinase signaling, and blocking or redirecting kinase binding is a validated therapeutic strategy. Understanding these interactions at the molecular level supports the design of selective inhibitors and the interpretation of drug resistance mutations.
• Defines substrate recognition and targeting for protein kinases.
• Underlies the mechanism of action of kinase inhibitors used in cancer therapy.
• Enables allosteric and non-ATP-competitive inhibition strategies.
• Supports scaffold and anchoring functions that control kinase localization.
• Provides a framework for classifying kinase binding pockets and predicting selectivity.
• Links directly to phosphorylation-dependent signaling in cancer and other diseases.
• Is a prerequisite for interpreting resistance mutations in kinase drug targets.
• Can be studied with structural, biochemical, and CRISPR-based cellular models.
Molecular Mechanism of protein kinase binding
Recognition of the kinase surface
In simple terms: A binding protein finds and sticks to a specific patch on the kinase surface.
Protein kinase binding begins with molecular recognition of a complementary surface on the kinase. This can involve the ATP-binding cleft, allosteric pockets, or protein-protein interfaces, and the specificity of the interaction depends on shape and chemical complementarity. Molecular modeling and binding-site classification studies have shown that these pockets can be grouped into families, which helps predict which proteins or small molecules will bind a given kinase.
Binding without direct ATP competition
In simple terms: Some proteins block a kinase without occupying the ATP pocket.
A new paradigm for protein kinase inhibition is blocking phosphorylation without directly targeting ATP binding. This means that a binding protein can inhibit a kinase by interacting with a regulatory or allosteric site, rather than by competing with ATP. Such non-ATP-competitive binding expands the range of possible regulatory interactions and drug design strategies.
Anchoring and scaffolding functions
In simple terms: Some binding proteins hold a kinase in a specific part of the cell.
Protein kinase binding is not limited to inhibition or substrate presentation; it can also anchor a kinase to a cellular compartment. FAM53C was identified as a cytosolic-anchoring inhibitory binding protein of the kinase DYRK1A, showing that binding can control both activity and localization. This anchoring function is a key example of how protein kinase binding shapes signaling outcomes.
Complex-directed drug binding
In simple terms: Some drugs bind a kinase only when it is paired with a partner protein.
The drug trametinib binds KSR-bound MEK, demonstrating that protein kinase binding interfaces can be targeted in a complex-dependent manner. Structural analysis of this interaction revealed how the drug recognizes the MEK-KSR complex, providing a basis for understanding allosteric and complex-directed inhibition. This illustrates that protein kinase binding is not only a biological function but also a druggable interface.
Cofactors and regulation
In simple terms: Binding can depend on ions, nucleotides, or other cofactors.
Some protein kinase binding events are influenced by cofactors such as calcium. A Ca2+-dependent protein kinase activity associated with serotonin binding protein was reported, indicating that ion-dependent regulation can contribute to kinase-binding complexes. In addition, flavonoid compounds can act as protein kinase inhibitors through direct binding, showing that small molecules can modulate these interactions.
Key Genes Involved in GO:0019901 protein kinase binding
The following genes and proteins are representative examples of proteins that bind protein kinases or are themselves kinases whose binding interfaces are studied.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DYRK1A | Kinase bound and inhibited by FAM53C | Model for cytosolic anchoring and kinase inhibition |
| FAM53C | Cytosolic-anchoring inhibitory binding protein of DYRK1A | Example of a non-kinase protein that binds a kinase |
| MEK1/2 (MAP2K1/MAP2K2) | Kinase bound by KSR and targeted by trametinib | Model for complex-directed drug binding |
| KSR1 | Scaffold that binds MEK | Model for kinase-scaffold complexes |
| BRAF | Kinase in the MAPK pathway | Relevant to kinase binding and inhibitor design |
| CDK2 | Cyclin-dependent kinase | Model for ATP-pocket binding and inhibitor design |
| CDK4 | Cyclin-dependent kinase | Model for kinase binding pocket classification |
| EGFR | Receptor tyrosine kinase | Model for kinase inhibitor binding |
| ABL1 | Non-receptor tyrosine kinase | Model for kinase inhibitor binding and resistance |
| SRC | Non-receptor tyrosine kinase | Model for kinase binding and signaling |
| AKT1 | Serine/threonine kinase | Model for kinase binding in survival signaling |
| MAPK1 (ERK2) | Serine/threonine kinase | Model for substrate and scaffold binding |
| MAPK3 (ERK1) | Serine/threonine kinase | Model for pathway kinase binding |
| PKA (PRKACA) | cAMP-dependent protein kinase | Model for kinase binding and regulation |
| CAMK2 | Ca2+/calmodulin-dependent kinase | Model for Ca2+-dependent kinase binding |
| GSK3B | Serine/threonine kinase | Model for kinase binding and inhibitor studies |
| JAK2 | Janus kinase | Model for kinase binding in cytokine signaling |
How Is protein kinase binding Regulated?
Protein kinase binding is regulated at multiple levels. Binding can be controlled by cofactors such as calcium, as shown for a Ca2+-dependent protein kinase activity associated with serotonin binding protein. Small molecules, including flavonoids, can directly bind and inhibit protein kinases, indicating that chemical regulation of these interactions is possible. In addition, binding can be allosteric and independent of ATP competition, which provides a regulatory mechanism distinct from substrate or ATP availability. Complex formation with scaffold proteins such as KSR can also regulate drug binding and kinase activity.
protein kinase binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DYRK1A | Neurological signaling and kinase regulation | Knockout or point-mutation cell model of DYRK1A binding to FAM53C |
| MEK1/2 | Cancer and MAPK pathway signaling | Knock-in of drug-resistance mutations at the trametinib binding interface |
| KSR1 | Cancer and scaffold-dependent kinase activation | Knockout of KSR1 to test complex-directed drug binding |
| EGFR | Cancer and kinase inhibitor response | Point-mutation knock-in of gatekeeper residues affecting inhibitor binding |
| ABL1 | Leukemia and kinase inhibitor resistance | Overexpression or knock-in of BCR-ABL1 binding variants |
Cancer
Protein kinase binding is central to cancer biology because many oncogenic kinases depend on binding interactions for activation and substrate targeting. Flavonoids have been studied as protein kinase inhibitors for cancer chemoprevention through direct binding and molecular modeling. Kinase inhibitors such as trametinib act on kinase complexes, and understanding these binding events is essential for therapy.
Neurological and signaling disorders
Kinase binding proteins can control neuronal signaling. FAM53C binds and anchors DYRK1A in the cytosol, and DYRK1A is linked to neurological functions. A Ca2+-dependent protein kinase activity associated with serotonin binding protein further suggests that kinase binding participates in neurotransmitter-related processes.
Drug resistance and selectivity
Mutations that alter kinase binding can affect drug efficacy. The structural basis of trametinib action at KSR-bound MEK highlights how binding interfaces influence drug response. Binding pocket classification and molecular recognition studies help predict selectivity and resistance.
From protein kinase binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a kinase-binding protein alter kinase activity? | CRISPR knockout of the binding protein |
| Does a specific binding interface residue control interaction? | Point mutation knock-in at the interface |
| Can a binding protein be tagged for localization studies? | Tagged knock-in of the endogenous locus |
| Does overexpression of a binding protein inhibit a kinase? | Overexpression cell model |
| Which genes are required for kinase binding-dependent signaling? | CRISPR library screening |
| How does a drug affect kinase complex binding? | Knock-in of drug-binding site mutations plus treatment |
How to Study the protein kinase binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Binding assay | Direct physical interaction with a kinase | Testing candidate binding proteins |
| Kinase activity assay | Phosphorylation of substrates | Testing inhibition or activation by binding |
| Structural biology | Three-dimensional binding interface | Rationalizing drug binding to kinase complexes |
| Molecular modeling | Predicted binding poses and affinities | Virtual screening of kinase binders |
| Binding-site classification | Similarity of kinase pockets | Predicting selectivity and off-target binding |
| CRISPR knockout | Loss-of-function effect of a binding protein | Testing causal role in kinase signaling |
| CRISPR knock-in | Effect of a specific binding-site mutation | Modeling drug resistance or interface disruption |
| CRISPR library screening | Genome-wide requirement for a binding-dependent phenotype | Identifying modifiers of kinase binding pathways |
Binding assays and structural biology
Direct binding of proteins or small molecules to kinases can be measured using biochemical binding assays and structural methods. Molecular modeling and binding-site classification have been used to study protein kinase binding pockets. Structural analysis of trametinib at KSR-bound MEK provides a template for complex-directed binding studies.
Kinase activity and phosphorylation profiling
Because protein kinase binding often affects phosphorylation, kinase activity assays and phospho-profiling are used to test functional consequences. The concept of blocking phosphorylation without directly targeting ATP binding illustrates how activity readouts can distinguish binding mechanisms. Ca2+-dependent kinase activity associated with serotonin binding protein was demonstrated using activity measurements.
CRISPR-based cellular models
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of kinase-binding interactions in cells. For example, knockout or overexpression of FAM53C can test its role as a DYRK1A-binding protein. Knock-in of mutations at drug-binding interfaces can test resistance mechanisms.
Library screening and bioinformatics
CRISPR library screening can identify genes that modulate kinase binding-dependent pathways. Bioinformatics and binding-site classification help prioritize candidate interactions and predict selectivity. These approaches are complementary to structural and biochemical studies.
How CRISPR Can Be Used to Study GO:0019901 protein kinase binding
Knockout
CRISPR knockout of a protein kinase binding protein can reveal whether the interaction is required for kinase activity, localization, or downstream signaling. For example, knocking out FAM53C would test its role as an inhibitory binding protein of DYRK1A. Knockout of scaffold proteins such as KSR1 can test complex-dependent drug action.
Point Mutation
Point mutation knock-in can disrupt a specific binding interface without removing the entire protein. This is useful for testing residues that mediate kinase binding or drug recognition, as illustrated by structural studies of trametinib at KSR-bound MEK. Point mutations in kinase binding pockets can also model inhibitor resistance.
Knock-in
Knock-in of tags or reporter sequences allows visualization and biochemical isolation of kinase-binding complexes at endogenous expression levels. Tagged knock-in of a binding protein such as FAM53C would enable tracking of its interaction with DYRK1A. Knock-in of disease-associated variants can test their effect on kinase binding.
Overexpression
Overexpression of a kinase-binding protein can test whether increased binding inhibits or redirects kinase activity. Overexpression of FAM53C would be expected to enhance cytosolic anchoring of DYRK1A based on its reported function. Overexpression of kinase inhibitors or binding domains can also be used to probe pathway dependence.
How EDITGENE Supports protein kinase binding Research
Researchers studying protein kinase binding-related genes often need to determine whether a candidate gene is causally involved in kinase regulation, drug response, or disease. EDITGENE provides CRISPR-based cell models and screening services to test these hypotheses directly in relevant cellular contexts.
Contact EDITGENE today to design your custom CRISPR model for protein kinase binding research.
Frequently Asked Questions About protein kinase binding
What is protein kinase binding (GO:0019901)?
Protein kinase binding is a molecular function defined as binding to a protein kinase, any enzyme that catalyzes the transfer of a phosphate group, usually from ATP, to a protein substrate.
What genes are involved in protein kinase binding?
Examples include DYRK1A and its binding protein FAM53C, MEK1/2 and KSR1, and kinases such as EGFR, ABL1, and CDK2 that are studied for binding interactions.
How does protein kinase binding regulate signaling?
Binding can recruit substrates, inhibit kinase activity, anchor kinases to compartments, or scaffold complexes, as shown for FAM53C-DYRK1A and KSR-MEK.
Can protein kinase binding be inhibited without targeting ATP?
Yes, a new paradigm for protein kinase inhibition is blocking phosphorylation without directly targeting ATP binding.
What diseases are linked to protein kinase binding?
Cancer and neurological signaling disorders are prominent examples, with kinase inhibitors such as trametinib acting on kinase complexes.
How is protein kinase binding studied experimentally?
Common methods include binding assays, kinase activity assays, structural biology, molecular modeling, and CRISPR-based cellular models.
What is the role of FAM53C in protein kinase binding?
FAM53C was identified as a cytosolic-anchoring inhibitory binding protein of the kinase DYRK1A.
How does trametinib interact with kinase binding?
Trametinib binds KSR-bound MEK, and structural analysis revealed the basis for its action at this kinase complex.
Can CRISPR be used to study protein kinase binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of kinase-binding proteins and interfaces.
What methods predict protein kinase binding pockets?
Molecular modeling and binding-site classification using tools such as Cavbase have been used to classify kinase binding sites.
Conclusion
GO:0019901 protein kinase binding is a fundamental molecular function that governs how kinases are recognized, inhibited, anchored, and targeted by drugs. Its study spans structural biology, biochemistry, and CRISPR-based cell modeling, with direct relevance to cancer and neurological disease. Understanding these interactions provides a rational basis for designing selective kinase inhibitors and interpreting resistance mechanisms.
References
- 1. Hou DX et al.. 2010. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling.. Antioxid Redox Signal 13(5):691-719 PMID: 20070239
- 2. Bogoyevitch MA et al.. 2007. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.. Drug Discov Today 12(15-16):622-33 PMID: 17706543
- 3. Miyata Y et al.. 2023. Identification of FAM53C as a cytosolic-anchoring inhibitory binding protein of the kinase DYRK1A.. Life Sci Alliance 6(12) PMID: 37802655
- 4. Khan ZM et al.. 2020. Structural basis for the action of the drug trametinib at KSR-bound MEK.. Nature 588(7838):509-514 PMID: 32927473
- 5. Liao JJ. 2007. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors.. J Med Chem 50(3):409-24 PMID: 17266192
- 6. Adlersberg M et al.. 1987. A Ca2+-dependent protein kinase activity associated with serotonin binding protein.. J Neurochem 49(4):1105-15 PMID: 3040904
- 7. Koch P et al.. 2018. Special Issue: Kinase inhibitors.. Molecules 23(7) PMID: 30037125
- 8. Kuhn D et al.. 2007. Functional classification of protein kinase binding sites using Cavbase.. ChemMedChem 2(10):1432-47 PMID: 17694525
